Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

June 8, 2020

Primary Completion Date

July 23, 2023

Study Completion Date

July 23, 2023

Conditions
Acute Myeloid Leukemia, in RelapseMyelodysplastic Syndromes
Interventions
DRUG

CB-5339

25mg and 75mg capsules

Trial Locations (10)

2010

St. Vincent Hospital, Sydney, NSW, Darlinghurst

3002

Epworth Healthcare, Melbourne

6000

Haematology Clinical Trials Unit, Royal Perth Hospital, Perth

10021

Memorial Sloan Kettering Cancer Center, New York

10065

Weill Cornel Medical Center, New York

29607

Saint Francis Hospital Cancer Center, Greenville

44122

Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland

66205

KU Clinical Research Center, Fairway

77030

MD Anderson Cancer Cancer, Houston

90033

USC Norris Comprehensive Cancer Center, Los Angeles

Sponsors
All Listed Sponsors
lead

Cleave Therapeutics, Inc.

INDUSTRY